Calcitriol Use in CKD Stage 5D on Dialysis

Introduction to Calcitriol Therapy

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that calcitriol remains an acceptable treatment option for PTH-lowering therapy in dialysis patients with CKD stage 5D, but it should be used cautiously due to significant risks of hypercalcemia and hyperphosphatemia, particularly in patients with cardiovascular disease 1, 2

PTH-lowering therapy is indicated when intact PTH levels fall outside the target range of approximately 2 to 9 times the upper normal limit for the assay, and treatment decisions should be based on serial assessments of phosphate, calcium, and PTH levels considered together, not PTH alone 2, 3
Marked changes in PTH in either direction within the target range should prompt initiation or modification of therapy to prevent progression outside this range 2

The 2017 KDIGO guidelines list treatment options in alphabetical order without preference: calcimimetics, calcitriol, vitamin D analogs, or combinations thereof, reflecting ongoing controversy 1, 2
No randomized trials have demonstrated that calcitriol improves patient-centered outcomes, such as mortality or cardiovascular events, in dialysis patients 4
The EVOLVE trial showed potential benefits with cinacalcet on secondary endpoints, though the primary endpoint was negative, creating division among guideline authors about first-line recommendations 4

Hypercalcemia must be strictly avoided in all CKD stage 5D patients, and immediately discontinuing calcitriol if hypercalcemia develops is recommended until normocalcemia returns 2, 5
Restricting calcium-based phosphate binder doses in adult dialysis patients receiving any phosphate-lowering treatment is recommended to prevent calcium overload 2, 3
Total elemental calcium intake should be carefully monitored to prevent calcium overload, and maintaining a calcium-phosphorus product below 55 mg²/dL² can reduce extraskeletal calcification risk 3, 5

Patients with known vascular or valvular calcification should be considered at highest cardiovascular risk, and this information should guide CKD-MBD management decisions, specifically arguing for more conservative calcium and vitamin D analog use 2
Consider calcimimetics as first-line therapy in this population to avoid the calcemic effects of calcitriol 1, 4

During the maintenance phase, calcium and phosphate levels should be monitored every 1-3 months, and PTH levels should be monitored every 3-6 months 6

Do not use calcitriol to normalize PTH completely, as some elevation is appropriate and attempts at full suppression increase hypercalcemia risk 2